Patient-reported outcomes in a phase II randomised study of regorafenib compared with lomustine in patients with relapsed glioblastoma (the REGOMA trial)

European Journal of Cancer ◽

10.1016/j.ejca.2021.06.055 ◽

2021 ◽

Vol 155 ◽

pp. 179-190

Author(s):

Giuseppe Lombardi ◽

Paola Del Bianco ◽

Alba A. Brandes ◽

Marica Eoli ◽

Roberta Rudà ◽

...

Keyword(s):

Phase Ii ◽

Patient Reported Outcomes ◽

Randomised Study ◽

Patient Reported

Download Full-text

Faculty Opinions recommendation of Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, Phase II study (SYMPHONY).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.726641973.793540485 ◽

2017 ◽

Author(s):

Lori Ann Birder

Keyword(s):

Overactive Bladder ◽

Phase Ii ◽

Combination Treatment ◽

Patient Reported Outcomes ◽

Phase Ii Study ◽

Double Blind ◽

Patient Reported ◽

Dose Ranging

Download Full-text

Greater fear of hypoglycaemia with premixed insulin than with basal-bolus insulin glargine and glulisine: patient-reported outcomes from a 60-week randomised study

Diabetes Obesity and Metabolism ◽

10.1111/dom.12328 ◽

2014 ◽

Vol 16 (11) ◽

pp. 1121-1127 ◽

Cited By ~ 5

Author(s):

W. H. Polonsky ◽

S. Thompson ◽

W. Wei ◽

M. C. Riddle ◽

S. Chaudhari ◽

...

Keyword(s):

Insulin Glargine ◽

Patient Reported Outcomes ◽

Premixed Insulin ◽

Randomised Study ◽

Patient Reported ◽

Bolus Insulin ◽

Basal Bolus

Download Full-text

Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours

ESMO Open ◽

10.1016/j.esmoop.2021.100113 ◽

2021 ◽

Vol 6 (3) ◽

pp. 100113

Author(s):

L. Paz-Ares ◽

F. Barlesi ◽

S. Siena ◽

M.-J. Ahn ◽

A. Drilon ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii ◽

Cell Lung Cancer ◽

Patient Reported Outcomes ◽

Small Cell ◽

Solid Tumours ◽

Small Cell Lung ◽

Patient Reported

Download Full-text

Prostate high dose-rate brachytherapy as monotherapy for prostate cancer: Late toxicity and patient reported outcomes from a randomized phase II clinical trial

Radiotherapy and Oncology ◽

10.1016/j.radonc.2020.12.021 ◽

2021 ◽

Vol 156 ◽

pp. 160-165

Author(s):

Mark Corkum ◽

Andrew Loblaw ◽

Yaser Hasan ◽

Hans T. Chung ◽

Chia-Lin Tseng ◽

...

Keyword(s):

Prostate Cancer ◽

Clinical Trial ◽

Dose Rate ◽

Phase Ii ◽

Patient Reported Outcomes ◽

Late Toxicity ◽

High Dose Rate ◽

High Dose ◽

Randomized Phase Ii ◽

Patient Reported

Download Full-text

385P Patient reported outcomes (PROs) analysis for patients with ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC) receiving entrectinib in the global phase II STARTRK-2 study

Annals of Oncology ◽

10.1016/j.annonc.2020.10.379 ◽

2020 ◽

Vol 31 ◽

pp. S1391-S1392

Author(s):

F. Barlesi ◽

J. Wolf ◽

M-J. Ahn ◽

R.C. Doebele ◽

L. Paz-Ares ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii ◽

Cell Lung Cancer ◽

Patient Reported Outcomes ◽

Small Cell ◽

Small Cell Lung ◽

Patient Reported

Download Full-text

PCN126 REVIEW OF PATIENT-REPORTED OUTCOMES IN PHASE II ONCOLOGY CLINICAL TRIALS

Value in Health ◽

10.1016/s1098-3015(11)72021-6 ◽

2010 ◽

Vol 13 (7) ◽

pp. A275

Author(s):

S Danheiser ◽

F Barkalow ◽

HW Finnern

Keyword(s):

Clinical Trials ◽

Phase Ii ◽

Patient Reported Outcomes ◽

Patient Reported ◽

Oncology Clinical Trials

Download Full-text

539P Patient-reported outcomes (PROs) from patients (Pts) with NTRK fusion-positive (NTRK-fp) solid tumours receiving entrectinib in the global phase II STARTRK-2 study

Annals of Oncology ◽

10.1016/j.annonc.2020.08.653 ◽

2020 ◽

Vol 31 ◽

pp. S471-S472

Author(s):

A.P. Conley ◽

G.D. Demetri ◽

R.C. Doebele ◽

A. Drilon ◽

L. Paz-Ares ◽

...

Keyword(s):

Phase Ii ◽

Patient Reported Outcomes ◽

Solid Tumours ◽

Patient Reported

Download Full-text

AT-07 * A PHASE II STUDY OF LAPATINIB AND DOSE-DENSE TEMOZOLOMIDE (TMZ) FOR ADULTS WITH RECURRENT EPENDYMOMA: PATIENT REPORTED OUTCOMES (PRO) FROM A CERN CLINICAL TRIAL

Neuro-Oncology ◽

10.1093/neuonc/nou237.7 ◽

2014 ◽

Vol 16 (suppl 5) ◽

pp. v9-v9 ◽

Cited By ~ 1

Author(s):

T. S. Armstrong ◽

E. Vera-Bolanos ◽

M. Gilbert ◽

Y. Yuan ◽

K. Wani ◽

...

Keyword(s):

Clinical Trial ◽

Phase Ii ◽

Patient Reported Outcomes ◽

Phase Ii Study ◽

Patient Reported ◽

Recurrent Ependymoma ◽

Dose Dense

Download Full-text

A phase II, multicenter, single-arm trial of eribulin as first or second line chemotherapy for HER2-negative advanced or metastatic breast cancer: Evaluation of efficacy, safety, and patient-reported outcomes.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.e13059 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. e13059-e13059 ◽

Cited By ~ 2

Author(s):

Mitsuhiko Iwamoto ◽

Kosei Kimura ◽

Satoru Tanaka ◽

Daigo Yamamoto ◽

Katsuhide Yoshidome ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Phase Ii ◽

Patient Reported Outcomes ◽

Metastatic Breast ◽

Second Line ◽

Second Line Chemotherapy ◽

Patient Reported ◽

Line Chemotherapy

Download Full-text

Efficacy and patient-reported outcomes with dose-intense temozolomide in patients with newly diagnosed pure and mixed anaplastic oligodendroglioma: a phase II multicenter study

Journal of Neuro-Oncology ◽

10.1007/s11060-014-1684-y ◽

2014 ◽

Vol 122 (1) ◽

pp. 111-119 ◽

Cited By ~ 12

Author(s):

Manmeet S. Ahluwalia ◽

Hao Xie ◽

Saurabh Dahiya ◽

Nooshin Hashemi-Sadraei ◽

David Schiff ◽

...

Keyword(s):

Phase Ii ◽

Multicenter Study ◽

Patient Reported Outcomes ◽

Anaplastic Oligodendroglioma ◽

Newly Diagnosed ◽

Patient Reported

Download Full-text